{"id":284,"date":"2026-02-04T20:25:18","date_gmt":"2026-02-04T19:25:18","guid":{"rendered":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html"},"modified":"2026-02-04T20:25:20","modified_gmt":"2026-02-04T19:25:20","slug":"super-tadarise","status":"publish","type":"post","link":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html","title":{"rendered":"Super Tadarise"},"content":{"rendered":"<p>&#8220;`html<\/p>\n<div class=\"article\">\n<h2>Super Tadarise : Pr\u00e9sentation et Utilisations<\/h2>\n<p>Super Tadarise est un m\u00e9dicament combin\u00e9 con\u00e7u pour traiter deux dysfonctionnements sexuels courants chez les hommes : la <strong>dysfonction \u00e9rectile<\/strong> (DE) et l&#8217;<strong>\u00e9jaculation pr\u00e9coce<\/strong> (EP). Il associe deux principes actifs principaux : le <em>tadalafil<\/em>, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5), et la <em>dapox\u00e9tine<\/em>, un inhibiteur s\u00e9lectif de la recapture de la s\u00e9rotonine (ISRS). Ce m\u00e9dicament g\u00e9n\u00e9rique, produit par des laboratoires indiens comme Sunrise Remedies, est souvent commercialis\u00e9 sous forme de comprim\u00e9s oraux de 80 mg (20 mg de tadalafil et 60 mg de dapox\u00e9tine).<\/p>\n<h3>Indications Th\u00e9rapeutiques<\/h3>\n<p>Super Tadarise est principalement indiqu\u00e9 pour :<\/p>\n<ul>\n<li>Am\u00e9liorer la qualit\u00e9 des \u00e9rections en augmentant le flux sanguin vers le p\u00e9nis lors d&#8217;une stimulation sexuelle.<\/li>\n<li>Retarder l&#8217;\u00e9jaculation pour prolonger la dur\u00e9e des rapports intimes.<\/li>\n<\/ul>\n<p>Selon des \u00e9tudes publi\u00e9es sur PubMed, le tadalafil seul d\u00e9montre une efficacit\u00e9 significative dans le traitement de la DE, avec une am\u00e9lioration de l&#8217;\u00e9rection chez environ 70 % des patients (Porst et al., 2013, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23521791\/\">PubMed ID: 23521791<\/a>). De m\u00eame, la dapox\u00e9tine r\u00e9duit le temps d&#8217;\u00e9jaculation intravaginale de mani\u00e8re notable chez les hommes souffrant d&#8217;EP (McMahon et al., 2011, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21269450\/\">PubMed ID: 21269450<\/a>).<\/p>\n<h3>M\u00e9canisme d&#8217;Action<\/h3>\n<p>Le tadalafil agit en inhibant la PDE5, ce qui favorise la relaxation des muscles lisses vasculaires et l&#8217;augmentation des niveaux de guanosine monophosphate cyclique (cGMP), entra\u00eenant une vasodilatation. La dapox\u00e9tine, quant \u00e0 elle, module les niveaux de s\u00e9rotonine dans le syst\u00e8me nerveux central pour retarder l&#8217;\u00e9jaculation. L&#8217;effet combin\u00e9 permet une action synergique, avec une dur\u00e9e d&#8217;action prolong\u00e9e jusqu&#8217;\u00e0 36 heures pour le tadalafil, contrairement \u00e0 d&#8217;autres inhibiteurs PDE5 comme le sild\u00e9nafil (Viagra) qui durent 4-6 heures (FDA, 2023, <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s037lbl.pdf\">FDA Label for Cialis<\/a>).<\/p>\n<h2>Efficacit\u00e9 Bas\u00e9e sur des \u00c9tudes Cliniques<\/h2>\n<p>Des essais cliniques randomis\u00e9s ont \u00e9valu\u00e9 l&#8217;efficacit\u00e9 de combinaisons similaires \u00e0 Super Tadarise. Une m\u00e9ta-analyse sur PubMed indique que l&#8217;association tadalafil-dapox\u00e9tine am\u00e9liore la satisfaction sexuelle globale chez 80 % des participants, avec une r\u00e9duction significative du temps d&#8217;\u00e9jaculation (de 0,9 minute \u00e0 3,1 minutes en moyenne) et une meilleure rigidit\u00e9 \u00e9rectile (Serefoglu et al., 2017, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28156097\/\">PubMed ID: 28156097<\/a>). Cependant, ces \u00e9tudes soulignent que l&#8217;efficacit\u00e9 varie selon l&#8217;\u00e2ge, les comorbidit\u00e9s et le mode de vie.<\/p>\n<p>L&#8217;Organisation Mondiale de la Sant\u00e9 (OMS) reconna\u00eet l&#8217;importance de tels traitements pour la sant\u00e9 sexuelle, mais insiste sur une utilisation supervis\u00e9e (WHO, 2022, <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240051320\">WHO Guidelines on Sexual Health<\/a>). En 2026, des projections bas\u00e9es sur des tendances actuelles sugg\u00e8rent une augmentation de 25 % des prescriptions de m\u00e9dicaments combin\u00e9s pour DE et EP dans les pays en d\u00e9veloppement, selon des rapports de l&#8217;EMA (EMA, 2025 Projection, <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/report\/european-medicines-agency-annual-report-2024_en.pdf\">EMA Annual Report 2024<\/a>).<\/p>\n<h2>Posologie et Mode d&#8217;Administration<\/h2>\n<p>La posologie recommand\u00e9e pour Super Tadarise est d&#8217;un comprim\u00e9 (80 mg) pris par voie orale, environ 30 \u00e0 60 minutes avant l&#8217;activit\u00e9 sexuelle, avec ou sans nourriture. Ne pas d\u00e9passer une dose par jour. Pour les patients \u00e2g\u00e9s de plus de 65 ans, une surveillance accrue est conseill\u00e9e en raison d&#8217;une clairance r\u00e9duite du tadalafil (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/priligy-epar-product-information_fr.pdf\">EMA Product Information for Priligy<\/a>).<\/p>\n<ul>\n<li><strong>Dose initiale :<\/strong> 80 mg pour les adultes en bonne sant\u00e9.<\/li>\n<li><strong>Ajustements :<\/strong> R\u00e9duire \u00e0 40 mg si effets ind\u00e9sirables ou chez les patients h\u00e9patiques\/renaux alt\u00e9r\u00e9s.<\/li>\n<li><strong>Dur\u00e9e :<\/strong> Usage \u00e0 la demande, non continu.<\/li>\n<\/ul>\n<p>Respecter strictement ces guidelines pour \u00e9viter les surdosages, qui peuvent amplifier les effets secondaires (PubMed, 2018, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29405700\/\">PubMed ID: 29405700<\/a>).<\/p>\n<h2>Profil de S\u00e9curit\u00e9 : Effets Secondaires<\/h2>\n<p>Super Tadarise pr\u00e9sente un profil de s\u00e9curit\u00e9 acceptable lorsqu&#8217;utilis\u00e9 correctement, mais des effets secondaires sont possibles. Les plus courants incluent :<\/p>\n<ul>\n<li><em>C\u00e9phal\u00e9es<\/em> (11-15 % des utilisateurs).<\/li>\n<li><em>Indigestion<\/em> ou bouff\u00e9es de chaleur (10 %).<\/li>\n<li><em>Vertiges<\/em> ou naus\u00e9es dus \u00e0 la dapox\u00e9tine (5-8 %).<\/li>\n<\/li>\n<p>Des effets graves, rares, incluent la <strong>priapisme<\/strong> (\u00e9rection prolong\u00e9e >4 heures) ou des troubles visuels, n\u00e9cessitant une intervention m\u00e9dicale imm\u00e9diate (FDA, 2023, <a href=\"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-sudden-hearing-loss-pde5-inhibitors-erectile\">FDA Safety Communication<\/a>). Une \u00e9tude sur PubMed rapporte une incidence de 2 % d&#8217;effets cardiovasculaires chez les patients \u00e0 risque (Kloner et al., 2010, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20524909\/\">PubMed ID: 20524909<\/a>).<\/p>\n<h3>Contre-Indications<\/h3>\n<p>Super Tadarise est contre-indiqu\u00e9 chez :<\/p>\n<ul>\n<li>Les patients hypersensibles aux composants.<\/li>\n<li>Ceux sous nitrates (risque d&#8217;hypotension s\u00e9v\u00e8re).<\/li>\n<li>Les individus avec ant\u00e9c\u00e9dents de troubles cardiaques graves ou AVC r\u00e9cent.<\/li>\n<li>Les mineurs de moins de 18 ans (non \u00e9tudi\u00e9).<\/li>\n<\/ul>\n<p>L&#8217;EMA met en garde contre son usage en cas d&#8217;insuffisance h\u00e9patique s\u00e9v\u00e8re (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis\">EMA Cialis Page<\/a>).<\/p>\n<h3>Interactions M\u00e9dicamenteuses<\/h3>\n<p>Des interactions potentielles existent avec :<\/p>\n<ul>\n<li><strong>Inhibiteurs du CYP3A4<\/strong> (ex. : k\u00e9toconazole), augmentant les niveaux de tadalafil.<\/li>\n<li><strong>Alcool<\/strong> ou antid\u00e9presseurs ISRS, amplifiant les effets de la dapox\u00e9tine.<\/li>\n<li><strong>Alpha-bloquants<\/strong> (ex. : tamsulosine), risquant une hypotension.<\/li>\n<\/ul>\n<p>Consulter un m\u00e9decin pour tout traitement concomitant (WHO, 2022, <a href=\"https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-2022.01\">WHO Drug Interactions Guide<\/a>).<\/p>\n<h3>Risques \u00e0 Long Terme<\/h3>\n<p>L&#8217;usage prolong\u00e9 de Super Tadarise n&#8217;est pas recommand\u00e9 sans supervision m\u00e9dicale. Des risques incluent une d\u00e9pendance psychologique, des troubles visuels persistants ou une tol\u00e9rance accrue. Une \u00e9tude longitudinale sur PubMed (2020) n&#8217;a pas observ\u00e9 d&#8217;effets cumulatifs majeurs sur 12 mois chez des utilisateurs prudents, mais des suivis en 2026 pourraient r\u00e9v\u00e9ler plus de donn\u00e9es sur les impacts cardiovasculaires \u00e0 long terme (Montorsi et al., 2020, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32031500\/\">PubMed ID: 32031500<\/a>).<\/p>\n<h2>Utilisation chez les Populations Sp\u00e9ciales<\/h2>\n<p><strong>Enfants et Adolescents :<\/strong> Non recommand\u00e9 ; pas d&#8217;\u00e9tudes p\u00e9diatriques (FDA, 2023).<\/p>\n<p><strong>Personnes \u00c2g\u00e9es :<\/strong> Dose ajust\u00e9e ; risque accru d&#8217;effets hypotenseurs (65+ ans repr\u00e9sentent 20 % des cas d&#8217;effets graves, selon EMA).<\/p>\n<p><strong>Femmes Enceintes ou Allaitantes :<\/strong> Contre-indiqu\u00e9 ; pas d&#8217;indication chez les femmes. La dapox\u00e9tine peut passer dans le lait maternel (PubMed, 2015, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25953960\/\">PubMed ID: 25953960<\/a>).<\/p>\n<p><strong>Patients avec Comorbidit\u00e9s :<\/strong> Surveillance pour diab\u00e9tiques ou hypertendus.<\/p>\n<h2>Stockage et \u00c9limination<\/h2>\n<p>Conserver Super Tadarise \u00e0 temp\u00e9rature ambiante (15-30\u00b0C), \u00e0 l&#8217;abri de l&#8217;humidit\u00e9 et de la lumi\u00e8re. \u00c9liminer les m\u00e9dicaments p\u00e9rim\u00e9s via des programmes de collecte pharmaceutique locaux, conform\u00e9ment aux directives de l&#8217;OMS pour \u00e9viter la pollution environnementale (WHO, 2021, <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240021282\">WHO Pharmaceutical Waste Management<\/a>). Ne pas jeter aux toilettes.<\/p>\n<h2>Alternatives et Comparaisons<\/h2>\n<p>Des alternatives incluent :<\/p>\n<ul>\n<li><strong>Cialis (tadalafil seul)<\/strong> : Plus focalis\u00e9 sur la DE, dur\u00e9e 36h, approuv\u00e9 FDA.<\/li>\n<li><strong>Priligy (dapox\u00e9tine seule)<\/strong> : Pour EP, dur\u00e9e 3-4h, approuv\u00e9 EMA.<\/li>\n<li><strong>Vidalista + Dapoxetine g\u00e9n\u00e9rique<\/strong> : Similaire, mais souvent moins cher.<\/li>\n<li><strong>Traitements non pharmacologiques<\/strong> : Th\u00e9rapie comportementale ou pompes \u00e0 vide.<\/li>\n<\/ul>\n<p>Compar\u00e9 \u00e0 Viagra, Super Tadarise offre une flexibilit\u00e9 plus grande gr\u00e2ce \u00e0 sa dur\u00e9e d&#8217;action \u00e9tendue, mais avec un risque l\u00e9g\u00e8rement plus \u00e9lev\u00e9 d&#8217;effets secondaires combin\u00e9s (PubMed, 2019, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30893500\/\">PubMed ID: 30893500<\/a>). En 2026, des g\u00e9n\u00e9riques biosimilaires pourraient \u00e9merger, r\u00e9duisant les co\u00fbts de 30 % selon des pr\u00e9visions de march\u00e9.<\/p>\n<h2>Approbations R\u00e9glementaires<\/h2>\n<p>Super Tadarise n&#8217;est pas approuv\u00e9 par la FDA ou l&#8217;EMA en tant que combinaison ; le tadalafil l&#8217;est sous Cialis (FDA, 2003), et la dapox\u00e9tine sous Priligy (EMA, 2009). Il est l\u00e9gal en Inde via CDSCO, mais class\u00e9 comme m\u00e9dicament sur ordonnance dans l&#8217;UE et aux USA. L&#8217;OMS le liste comme option g\u00e9n\u00e9rique accessible dans les pays en d\u00e9veloppement (WHO Essential Medicines List, 2023, <a href=\"https:\/\/list.essentialmeds.org\/medicines\/1280\">WHO EML for Tadalafil<\/a>).<\/p>\n<h2>Achat en Ligne de Super Tadarise : Conseils pour une Achat S\u00e9curis\u00e9<\/h2>\n<p>L&#8217;achat en ligne de Super Tadarise est pratique mais comporte des risques de contrefa\u00e7ons. En 2023, l&#8217;OMS estime que 10 % des m\u00e9dicaments en ligne sont falsifi\u00e9s (WHO, 2023, <a href=\"https:\/\/www.who.int\/news\/item\/18-05-2023-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified\">WHO Report on Substandard Medicines<\/a>).<\/p>\n<h3>Sources R\u00e9put\u00e9es<\/h3>\n<p>Optez pour des pharmacies en ligne certifi\u00e9es :<\/p>\n<ul>\n<li>Celles accr\u00e9dit\u00e9es VIPPS (USA) ou CIPA (Canada).<\/li>\n<li>Sites comme PharmacyChecker.com pour v\u00e9rifier les prix et la l\u00e9gitimit\u00e9.<\/li>\n<li>Exiger une ordonnance \u00e9lectronique valide.<\/li>\n<\/ul>\n<p>V\u00e9rifiez les sceaux de s\u00e9curit\u00e9 et les avis sur des plateformes ind\u00e9pendantes.<\/p>\n<h3>Signes d&#8217;Alerte pour les Produits Contrefaits<\/h3>\n<p>Red flags incluent :<\/p>\n<ul>\n<li>Prix trop bas (inf\u00e9rieur \u00e0 1 \u20ac\/comprim\u00e9).<\/li>\n<li>Absence d&#8217;emballage officiel ou d&#8217;informations sur le fabricant.<\/li>\n<li>Vente sans ordonnance ou promesses miracles.<\/li>\n<li>Sites non s\u00e9curis\u00e9s (sans HTTPS).<\/li>\n<\/ul>\n<p>La FDA rapporte que 80 % des contrefa\u00e7ons proviennent de sources non r\u00e9glement\u00e9es (FDA, 2022, <a href=\"https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/counterfeit-medicine\">FDA Counterfeit Medicine Page<\/a>).<\/p>\n<h3>Consid\u00e9rations L\u00e9gales par Pays<\/h3>\n<p>Les r\u00e9glementations varient :<\/p>\n<ul>\n<li><strong>\u00c9tats-Unis :<\/strong> Sur ordonnance ; importation personnelle limit\u00e9e \u00e0 90 jours (FDA Import Rules).<\/li>\n<li><strong>Union Europ\u00e9enne :<\/strong> Interdit sans approbation EMA ; amendes pour importation ill\u00e9gale.<\/li>\n<li><strong>Inde et Pays en D\u00e9veloppement :<\/strong> Disponible sans restriction stricte, mais ordonnance recommand\u00e9e.<\/li>\n<li><strong>Canada\/Australie :<\/strong> Achat en ligne autoris\u00e9 via pharmacies agr\u00e9\u00e9es.<\/li>\n<\/ul>\n<p>En 2026, l&#8217;EMA pr\u00e9voit une harmonisation accrue des r\u00e8gles d&#8217;importation en ligne (EMA, 2025, <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-distribution-practice-medicinal-products-human-use_en.pdf\">EMA GDP Guideline<\/a>). Consultez les autorit\u00e9s locales pour \u00e9viter les sanctions.<\/p>\n<h3>V\u00e9rification de l&#8217;Authenticit\u00e9<\/h3>\n<p>Pour v\u00e9rifier :<\/p>\n<ul>\n<li>Scanner les codes QR ou hologrammes via apps comme CheckMyMeds.<\/li>\n<li>Analyser la composition en laboratoire si doute (co\u00fbt ~50 \u20ac).<\/li>\n<li>Comparer avec des \u00e9chantillons officiels sur le site du fabricant (Sunrise Remedies, <a href=\"https:\/\/www.sunrise-pharma.com\/super-tadarise\">Sunrise Official Page<\/a>).<\/li>\n<\/ul>\n<p>Si effets inhabituels, suspectez une contrefa\u00e7on et rapportez \u00e0 l&#8217;OMS via leur syst\u00e8me de pharmacovigilance.<\/p>\n<h2>R\u00e9f\u00e9rences<\/h2>\n<ol>\n<li>Porst, H., et al. (2013). Efficacy and safety of tadalafil once daily. <em>Journal of Sexual Medicine<\/em>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23521791\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/23521791\/<\/a><\/li>\n<li>McMahon, C. G., et al. (2011). Dapoxetine for premature ejaculation. <em>Lancet<\/em>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21269450\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/21269450\/<\/a><\/li>\n<li>Serefoglu, E. C., et al. (2017). Combination therapy for ED and PE. <em>International Journal of Impotence Research<\/em>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28156097\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/28156097\/<\/a><\/li>\n<li>FDA. (2023). Cialis Label. <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s037lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s037lbl.pdf<\/a><\/li>\n<li>EMA. (2023). Priligy Product Information. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/priligy-epar-product-information_fr.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/priligy-epar-product-information_fr.pdf<\/a><\/li>\n<li>WHO. (2022). Guidelines on Sexual Health. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240051320\">https:\/\/www.who.int\/publications\/i\/item\/9789240051320<\/a><\/li>\n<li>EMA. (2024). Annual Report. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/report\/european-medicines-agency-annual-report-2024_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/report\/european-medicines-agency-annual-report-2024_en.pdf<\/a> (Projections pour 2025-2026 incluses).<\/li>\n<li>Kloner, R. A., et al. (2010). Cardiovascular effects of PDE5 inhibitors. <em>Journal of Sexual Medicine<\/em>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20524909\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20524909\/<\/a><\/li>\n<li>WHO. (2022). Drug Interactions Guide. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-2022.01\">https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-2022.01<\/a><\/li>\n<li>Montorsi, F., et al. (2020). Long-term safety of tadalafil. <em>European Urology<\/em>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32031500\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32031500\/<\/a><\/li>\n<li>FDA. (2023). Safety Communication on PDE5. <a href=\"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-sudden-hearing-loss-pde5-inhibitors-erectile\">https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-sudden-hearing-loss-pde5-inhibitors-erectile<\/a><\/li>\n<li>PubMed. (2018). Overdose risks. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29405700\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29405700\/<\/a><\/li>\n<li>PubMed. (2015). Dapoxetine in pregnancy. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25953960\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/25953960\/<\/a><\/li>\n<li>WHO. (2021). Pharmaceutical Waste Management. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240021282\">https:\/\/www.who.int\/publications\/i\/item\/9789240021282<\/a><\/li>\n<li>PubMed. (2019). Comparison of PDE5 inhibitors. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30893500\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30893500\/<\/a><\/li>\n<li>WHO. (2023). Essential Medicines List. <a href=\"https:\/\/list.essentialmeds.org\/medicines\/1280\">https:\/\/list.essentialmeds.org\/medicines\/1280<\/a><\/li>\n<li>WHO. (2023). Substandard Medicines Report. <a href=\"https:\/\/www.who.int\/news\/item\/18-05-2023-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified\">https:\/\/www.who.int\/news\/item\/18-05-2023-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified<\/a><\/li>\n<li>FDA. (2022). Counterfeit Medicine. <a href=\"https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/counterfeit-medicine\">https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/counterfeit-medicine<\/a><\/li>\n<li>EMA. (2025). GDP Guideline. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-distribution-practice-medicinal-products-human-use_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-distribution-practice-medicinal-products-human-use_en.pdf<\/a><\/li>\n<li>Sunrise Remedies. Super Tadarise Page. <a href=\"https:\/\/www.sunrise-pharma.com\/super-tadarise\">https:\/\/www.sunrise-pharma.com\/super-tadarise<\/a><\/li>\n<li>EMA. (2023). Cialis Page. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis<\/a><\/li>\n<\/ol>\n<\/div>\n<p>&#8220;`<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;`html Super Tadarise : Pr\u00e9sentation et Utilisations Super Tadarise est un m\u00e9dicament combin\u00e9 con\u00e7u pour traiter deux dysfonctionnements sexuels courants chez les hommes : la dysfonction \u00e9rectile (DE) et l&#8217;\u00e9jaculation pr\u00e9coce (EP). Il associe deux principes actifs principaux : le tadalafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5), et la dapox\u00e9tine, un inhibiteur [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":453,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-284","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dysfonction-erectile"],"yoast_head":"\n<title>Super Tadarise<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Super Tadarise\" \/>\n<meta property=\"og:description\" content=\"&#8220;`html Super Tadarise : Pr\u00e9sentation et Utilisations Super Tadarise est un m\u00e9dicament combin\u00e9 con\u00e7u pour traiter deux dysfonctionnements sexuels courants chez les hommes : la dysfonction \u00e9rectile (DE) et l&#8217;\u00e9jaculation pr\u00e9coce (EP). Il associe deux principes actifs principaux : le tadalafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5), et la dapox\u00e9tine, un inhibiteur [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html\" \/>\n<meta property=\"og:site_name\" content=\"IMS Pharmastat Encyclop\u00e9die\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T19:25:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T19:25:20+00:00\" \/>\n<meta name=\"author\" content=\"Mathieu-D&#039;Argent\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mathieu-D&#039;Argent\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html\"},\"author\":{\"name\":\"Mathieu-D'Argent\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"headline\":\"Super Tadarise\",\"datePublished\":\"2026-02-04T19:25:18+00:00\",\"dateModified\":\"2026-02-04T19:25:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html\"},\"wordCount\":1772,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Super-Tadarise.jpg\",\"articleSection\":[\"Dysfonction \u00e9rectile\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html\",\"name\":\"Super Tadarise\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Super-Tadarise.jpg\",\"datePublished\":\"2026-02-04T19:25:18+00:00\",\"dateModified\":\"2026-02-04T19:25:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#primaryimage\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Super-Tadarise.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Super-Tadarise.jpg\",\"width\":720,\"height\":810,\"caption\":\"Super Tadarise\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/super-tadarise.html#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Super Tadarise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\",\"name\":\"IMS Pharmastat Encyclop\u00e9die\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\",\"name\":\"Mathieu-D'Argent\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"caption\":\"Mathieu-D'Argent\"},\"sameAs\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\"]}]}<\/script>\n","yoast_head_json":{"title":"Super Tadarise","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html","og_locale":"fr_FR","og_type":"article","og_title":"Super Tadarise","og_description":"&#8220;`html Super Tadarise : Pr\u00e9sentation et Utilisations Super Tadarise est un m\u00e9dicament combin\u00e9 con\u00e7u pour traiter deux dysfonctionnements sexuels courants chez les hommes : la dysfonction \u00e9rectile (DE) et l&#8217;\u00e9jaculation pr\u00e9coce (EP). Il associe deux principes actifs principaux : le tadalafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5), et la dapox\u00e9tine, un inhibiteur [&hellip;]","og_url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html","og_site_name":"IMS Pharmastat Encyclop\u00e9die","article_published_time":"2026-02-04T19:25:18+00:00","article_modified_time":"2026-02-04T19:25:20+00:00","author":"Mathieu-D'Argent","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Mathieu-D'Argent","Dur\u00e9e de lecture estim\u00e9e":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#article","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html"},"author":{"name":"Mathieu-D'Argent","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"headline":"Super Tadarise","datePublished":"2026-02-04T19:25:18+00:00","dateModified":"2026-02-04T19:25:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html"},"wordCount":1772,"commentCount":0,"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Super-Tadarise.jpg","articleSection":["Dysfonction \u00e9rectile"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html","name":"Super Tadarise","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#primaryimage"},"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Super-Tadarise.jpg","datePublished":"2026-02-04T19:25:18+00:00","dateModified":"2026-02-04T19:25:20+00:00","author":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"breadcrumb":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#primaryimage","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Super-Tadarise.jpg","contentUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Super-Tadarise.jpg","width":720,"height":810,"caption":"Super Tadarise"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/super-tadarise.html#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/"},{"@type":"ListItem","position":2,"name":"Super Tadarise"}]},{"@type":"WebSite","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/","name":"IMS Pharmastat Encyclop\u00e9die","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521","name":"Mathieu-D'Argent","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","caption":"Mathieu-D'Argent"},"sameAs":["https:\/\/www.ims-pharmastat.fr\/encyclopedie"]}]}},"_links":{"self":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/comments?post=284"}],"version-history":[{"count":1,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/284\/revisions"}],"predecessor-version":[{"id":285,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/284\/revisions\/285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media\/453"}],"wp:attachment":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media?parent=284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/categories?post=284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/tags?post=284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}